Inova Alexandria Hospital issued the following announcement on Nov. 30
We congratulate members of our Inova Advanced Lung Disease and Transplant Program that were recently recognized by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) with the NHLBI Director's Award in the COVID-19 Response category for their work as part of a landmark clinical trial evaluating a drug, Fostamatinib, for the use in hospitalized patients with COVID-19. The results of this phase 2 trial appear very promising data with the manuscript recently published in Clinical Infectious Diseases. The pivotal phase 3 trial is currently underway which hopefully will confirm the utility of this novel COVID-19 therapy.
Learn more about Inova Lung Services at https://www.inova.org/lung and their work on the Fostamatinib clinical trial at https://www.inovanewsroom.org/?s=fostamatinib.
Original source can be found here.
Alerts Sign-up